Monoclonal Antibodies
Tracking # 20-1275019
$70.00
There are no ratings for this course
Learn moreCourse overview
Monoclonal antibodies are not our grandparents drugs. Monoclonal antibodies (mAb) offer discreet, directed therapeutic interventions for a variety of diseases. Target antigens range from infections organisms to cellular structures to mediators of inflammation. The characteristics of mAb favor general safety and efficacy. Their large molecular size removes many of the risks for adversity that characterize small drug molecules, with the most likely side effects reflecting allergies. However, as large proteins, many of the principles of pharmacology that we learned do not apply , at least in the way we were taught. Currently, six monoclonal antibodies are approved for use in animals in the United States. These include mAb that target parvovirus, an immune checkpoint cancer protein immune checkpoints (gilvmetmab) and mAb that target inflammatory mediators. These include lokivetmab, which targets IL-31 and the antinerve growth factor drugs frunevetmab (cats) and bedinvetmab (dogs).
Subject areas
This course counts toward the state boards and subject areas below.